文献速递神经肿瘤

新诊断WHO 2-3级成人脑膜瘤术后初始管理:荷兰脑肿瘤登记研究(2016-2021)结果

Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021).
PubMed 文献 · J Neurooncol · 2024-08-29

基于荷兰脑肿瘤登记(2016-2021)纳入393例新诊断WHO 2-3级成人脑膜瘤患者,评估术后6个月内辅助放疗的相关因素及5年生存关联;全切除后2级患者辅助放疗比例为22.2%(59/266),部分切除后为61.1%(58/95),3级患者为68.8%(22/32);3级疾病中辅助放疗与生存获益相关(HR 0.40,95%CI 0.16-0.95,P=0.04)。

要点

  • WHO 2级脑膜瘤全切除后辅助放疗比例为22.2%(59/266),部分切除后为61.1%(58/95)。
  • WHO 3级脑膜瘤辅助放疗比例为68.8%(22/32),部分切除后61.5%,全切除后73.7%。
  • 3级疾病中辅助放疗与生存获益相关(HR 0.40,95%CI 0.16-0.95,P=0.04)。

核心结论

  • 该全国性综述揭示中枢神经系统区域肿瘤委员会在2级脑膜瘤全切除后的管理存在差异,并证明3级脑膜瘤中辅助放疗的生存获益。

研究设计与样本

  • 研究纳入2016年至2021年间新诊断WHO 2-3级脑膜瘤的393例年龄≥18岁患者,使用荷兰脑肿瘤登记数据。
  • 采用逻辑回归分析识别术后6个月内辅助放疗的相关因素,并通过混合效应模型校正中枢神经系统区域肿瘤委员会间的变异。
  • 通过漏斗图评估肿瘤委员会间病例组合校正后放疗比例的变异。
  • 采用逆概率加权加速失效(Weibull)模型评估与5年生存的关联。
  • 分析基于多重插补数据集(m=10)以处理缺失数据。

主要发现

  • WHO 2级脑膜瘤全切除后辅助放疗比例为22.2%(59/266),部分切除后为61.1%(58/95)。
  • WHO 3级脑膜瘤辅助放疗比例为68.8%(22/32),其中部分切除后为61.5%,全切除后为73.7%。
  • 辅助放疗与3级、部分切除、骨侵犯及无多发病灶相关。
  • 2级脑膜瘤全切除后的管理在不同肿瘤委员会间存在差异。
  • 3级疾病中辅助放疗与生存获益相关(HR 0.40,95%CI 0.16-0.95,P=0.04)。

关键数值与推荐

  • WHO 2级脑膜瘤全切除后辅助放疗比例为22.2%(59/266)。
  • WHO 2级脑膜瘤部分切除后辅助放疗比例为61.1%(58/95)。
  • WHO 3级脑膜瘤辅助放疗比例为68.8%(22/32),部分切除后为61.5%,全切除后为73.7%。
  • 3级疾病中辅助放疗与生存获益相关(HR 0.40,95%CI 0.16-0.95,P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Meningiomas classified as grade 2-3 according to the World Health Organisation (WHO) require combined surgery and in most cases radiotherapy (RT). Their initial management was evaluated using the Dutch Brain Tumour Registry. METHODS: The study included 393 patients aged ≥ 18 years with newly diagnosed meningioma WHO grade 2-3 between 2016 and 2021. Factors associated with adjuvant RT < 6 months following surgery were identified using logistic regression analyses, thereby accounting for variation between CNS regional tumour boards through mixed-effect modelling. This variation was further assessed by funnel plots for case-mix adjusted ratios of RT across tumour boards. The association with patients' survival at 5 years was evaluated with inverse probability-weighted accelerated failure (Weibull) models. Analyses were performed on multiple imputed datasets (m = 10) to account for missing data. RESULTS: Adjuvant RT was administered to 22.2% (59/266) of patients with WHO grade 2 meningioma following a total resection, to 61.1% (58/95) following a partial resection, and to 68.8% (22/32) of patients with WHO grade 3 meningioma (61.5% after partial and 73.7% after total resection). RT was associated with grade 3, partial resection, bone invasion, and absence of multiple lesions. Management varied across tumour boards for grade 2 meningioma following total resection. Adjuvant RT was associated with survival benefit in case of grade 3 disease (hazard ratio: 0.40, 95%-confidence interval: 0.16-0.95, p = 0.04). CONCLUSION: This national review revealed variation across CNS regional tumour boards in the management of grade 2 meningioma following total resection, and demonstrated survival benefit of adjuvant RT in grade 3 meningioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ho VKY, Anten MM, Garst A, et al. Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021). J Neurooncol. 2024. PMID: 39207626. doi:10.1007/s11060-024-04730-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。